Ziopharm Oncology Inc (ZIOP) 13.38 $ZIOP
'Mad Money' Lightning Round: Sell, Sell, Sell Caesars Entertainment
at The Street - Fri Mar 06, 5:00AM CST
Cramer does not favor Control4, Ziopharm Oncology or Stratesys.
ZIOP: 13.38 (-0.43), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CTRL: 12.27 (-0.15)
3D Is Not The Place To Be - Cramer's Lightning Round (3/5/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 06, 4:49AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 5. Bearish Calls: Control4 Corp. (NASDAQ: CTRL ): "It is software for home entertainment, it is like no man! It's hard enough to be...
ZIOP: 13.38 (-0.43), VJET: 8.04 (-0.20), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CRM: 64.56 (-1.03), CTRL: 12.27 (-0.15)
Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?
at The Street - Thu Mar 05, 7:27PM CST
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
BID: 41.05 (-0.68), TSLA: 193.88 (-6.75), GWRE: 52.98 (-0.06), ZIOP: 13.38 (-0.43), GE: 25.42 (-0.40), LMT: 197.66 (-1.44), PCYC: 254.56 (+0.34), BX: 38.75 (-0.39), BMRN: 113.77 (+0.27), UTX: 119.43 (-1.36), HZO: 25.64 (+0.21), XOM: 85.63 (-1.11), CZR: 9.63 (-0.53), SBUX: 92.21 (-1.42), ETP: 57.31 (-0.74), SSYS: 62.34 (-1.97), RCPT: 140.09 (-1.10), COST: 149.54 (-1.63), ABBV: 55.64 (-1.22), TRAK: 40.21 (-0.51), ROL: 33.79 (-0.21), OA: 68.73 (+0.98), MOV: 23.86 (-0.59), MBLY: 37.84 (+0.82), CSCO: 28.92 (-0.38), URI: 90.50 (-1.56), CTRL: 12.27 (-0.15), AMZN: 380.09 (-7.74), GPRO: 40.13 (-0.95), KR: 74.35 (+0.04), WFC: 54.59 (-0.25), NXPI: 98.48 (-0.19), BMY: 65.12 (-0.93), BA: 153.12 (-1.35), HPQ: 33.18 (-0.82), DRI: 62.71 (-1.50), ISIS: 70.44 (-1.32), MCD: 97.13 (-1.98), CVX: 103.55 (-1.18), BABA: 84.40 (-1.70)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), LLY: 68.41 (-2.18), STML: 15.75 (-0.15)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)
Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market
at The Street - Fri Feb 27, 5:30AM CST
BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.
ZIOP: 13.38 (-0.43), FEYE: 42.83 (-1.08), TGTX: 15.16 (-0.43), BSFT: 31.45 (-0.29)
Ziopharm reports 4Q loss
Automated Insights - Fri Feb 27, 4:13AM CST
NEW YORK (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $10.4 million in its fourth quarter.
ZIOP: 13.38 (-0.43)
ZIOPHARM Oncology beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 4:56PM CST
ZIOP: 13.38 (-0.43)
Bullish Traders Take Another Dose of Ziopharm Oncology
at The Street - Tue Feb 24, 4:45AM CST
Bullish option traders are back in Ziopharm Oncology.
ZIOP: 13.38 (-0.43)
What Investors Should Expect From Janet Yellen’s Testimony on Tuesday
at The Street - Mon Feb 23, 2:21PM CST
The CNBC 'Fast Money Halftime' trading panel take a look at how stocks are likely to respond to Fed chair Janet Yellen's Senate testimony on Tuesday.
USO: 18.24 (-0.47), ZIOP: 13.38 (-0.43), EWG: 29.04 (-0.47), UCO: 8.11 (-0.37), OIH: 34.14 (-0.83), NEM: 23.30 (-2.00), SLXP: 158.01 (+0.57), DXJS: 33.17 (-0.04), TLT: 123.50 (-2.79), DXJ: 54.54 (+0.35), SPY: 207.50 (-2.96), QQQ: 107.41 (-1.23), EWU: 18.54 (-0.42), DE: 90.26 (-0.20), DIA: 178.40 (-2.77), IWM: 121.17 (-1.55), XLE: 76.78 (-1.40)
ZIOPHARMA Oncology Inc. Analyst Coverage Initiated: Brief Report Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Feb 17, 6:00AM CST
ZIOPHARMA Oncology Inc. (NASDAQ: ZIOP) a biotechnology company, engaged in the discovery and development of cancer therapies based in Boston, MA was one of the most traded companies today on the NASDAQ. ZIOP reached a new 52 week high and closed at nearly $10/share, up from a 52 week low of $2.31 in October of 2014.
ZIOP: 13.38 (-0.43)
ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
GlobeNewswire - Thu Feb 12, 6:36AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 13.38 (-0.43), JPM: 60.89 (-1.11)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 13.38 (-0.43), TROV: 6.20 (-0.09), CRR: 35.80 (-1.71), SLG: 123.54 (-4.37), WMS: 27.80 (+0.04), MLNK: 3.68 (+0.03), RXN: 27.24 (-0.31), KTWO: 19.33 (-0.68), PANW: 140.73 (-2.41), YHOO: 43.44 (-0.72), WHR: 203.42 (-7.40), UA: 74.80 (-0.99), GILD: 101.81 (-1.61), R: 91.48 (-2.38), SIX: 45.97 (-0.79), DATA: 92.34 (-3.16), TW: 129.11 (-2.40), MA: 90.79 (-2.02), NVET: 10.17 (-0.13), IPGP: 95.80 (-2.02)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (-0.06), ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66), BIOC: 3.10 (-0.26), KKR: 23.71 (+0.04), NBG: 1.43 (-0.08), ARO: 4.04 (-0.01), ANFI: 10.28 (-0.92), HOT: 80.69 (-0.06), COUP: 9.77 (+0.10), URBN: 38.89 (+0.15), VSTM: 8.33 (+0.34), SYN: 2.45 (+0.10), ANTH: 6.12 (+0.59), SALE: 18.26 (+0.06), CGEN: 8.13 (-0.14), DF: 15.88 (-0.13), CJJD: 2.81 (-0.08), MERU: 2.36 (-0.27)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 3.11 (-0.10), BLUE: 113.14 (+0.91), ZIOP: 13.38 (-0.43), MYGN: 35.13 (+0.34), PSTI: 3.10 (-0.11), PFE: 33.97 (-0.50), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), ASPX: 69.14 (-0.32), MNKD: 5.47 (-0.26), HSP: 87.90 (+0.05), ZTS: 45.78 (-0.68), ANTM: 145.16 (-1.69), WMGI: 26.21 (-0.11), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), THOR: 39.50 (-0.83), TEVA: 56.40 (-0.11), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), ARNA: 4.32 (+0.09)
'Mad Money' Lightning Round: Sell, Sell, Sell Caesars Entertainment
at The Street - Fri Mar 06, 5:00AM CST
Cramer does not favor Control4, Ziopharm Oncology or Stratesys.
ZIOP: 13.38 (-0.43), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CTRL: 12.27 (-0.15)
3D Is Not The Place To Be - Cramer's Lightning Round (3/5/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 06, 4:49AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 5. Bearish Calls: Control4 Corp. (NASDAQ: CTRL ): "It is software for home entertainment, it is like no man! It's hard enough to be...
ZIOP: 13.38 (-0.43), VJET: 8.04 (-0.20), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CRM: 64.56 (-1.03), CTRL: 12.27 (-0.15)
Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?
at The Street - Thu Mar 05, 7:27PM CST
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
BID: 41.05 (-0.68), TSLA: 193.88 (-6.75), GWRE: 52.98 (-0.06), ZIOP: 13.38 (-0.43), GE: 25.42 (-0.40), LMT: 197.66 (-1.44), PCYC: 254.56 (+0.34), BX: 38.75 (-0.39), BMRN: 113.77 (+0.27), UTX: 119.43 (-1.36), HZO: 25.64 (+0.21), XOM: 85.63 (-1.11), CZR: 9.63 (-0.53), SBUX: 92.21 (-1.42), ETP: 57.31 (-0.74), SSYS: 62.34 (-1.97), RCPT: 140.09 (-1.10), COST: 149.54 (-1.63), ABBV: 55.64 (-1.22), TRAK: 40.21 (-0.51), ROL: 33.79 (-0.21), OA: 68.73 (+0.98), MOV: 23.86 (-0.59), MBLY: 37.84 (+0.82), CSCO: 28.92 (-0.38), URI: 90.50 (-1.56), CTRL: 12.27 (-0.15), AMZN: 380.09 (-7.74), GPRO: 40.13 (-0.95), KR: 74.35 (+0.04), WFC: 54.59 (-0.25), NXPI: 98.48 (-0.19), BMY: 65.12 (-0.93), BA: 153.12 (-1.35), HPQ: 33.18 (-0.82), DRI: 62.71 (-1.50), ISIS: 70.44 (-1.32), MCD: 97.13 (-1.98), CVX: 103.55 (-1.18), BABA: 84.40 (-1.70)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), LLY: 68.41 (-2.18), STML: 15.75 (-0.15)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)
Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market
at The Street - Fri Feb 27, 5:30AM CST
BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.
ZIOP: 13.38 (-0.43), FEYE: 42.83 (-1.08), TGTX: 15.16 (-0.43), BSFT: 31.45 (-0.29)
Ziopharm reports 4Q loss
Automated Insights - Fri Feb 27, 4:13AM CST
NEW YORK (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $10.4 million in its fourth quarter.
ZIOP: 13.38 (-0.43)
ZIOPHARM Oncology beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 4:56PM CST
ZIOP: 13.38 (-0.43)
Bullish Traders Take Another Dose of Ziopharm Oncology
at The Street - Tue Feb 24, 4:45AM CST
Bullish option traders are back in Ziopharm Oncology.
ZIOP: 13.38 (-0.43)
What Investors Should Expect From Janet Yellen’s Testimony on Tuesday
at The Street - Mon Feb 23, 2:21PM CST
The CNBC 'Fast Money Halftime' trading panel take a look at how stocks are likely to respond to Fed chair Janet Yellen's Senate testimony on Tuesday.
USO: 18.24 (-0.47), ZIOP: 13.38 (-0.43), EWG: 29.04 (-0.47), UCO: 8.11 (-0.37), OIH: 34.14 (-0.83), NEM: 23.30 (-2.00), SLXP: 158.01 (+0.57), DXJS: 33.17 (-0.04), TLT: 123.50 (-2.79), DXJ: 54.54 (+0.35), SPY: 207.50 (-2.96), QQQ: 107.41 (-1.23), EWU: 18.54 (-0.42), DE: 90.26 (-0.20), DIA: 178.40 (-2.77), IWM: 121.17 (-1.55), XLE: 76.78 (-1.40)
ZIOPHARMA Oncology Inc. Analyst Coverage Initiated: Brief Report Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Feb 17, 6:00AM CST
ZIOPHARMA Oncology Inc. (NASDAQ: ZIOP) a biotechnology company, engaged in the discovery and development of cancer therapies based in Boston, MA was one of the most traded companies today on the NASDAQ. ZIOP reached a new 52 week high and closed at nearly $10/share, up from a 52 week low of $2.31 in October of 2014.
ZIOP: 13.38 (-0.43)
ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
GlobeNewswire - Thu Feb 12, 6:36AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 13.38 (-0.43), JPM: 60.89 (-1.11)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 13.38 (-0.43), TROV: 6.20 (-0.09), CRR: 35.80 (-1.71), SLG: 123.54 (-4.37), WMS: 27.80 (+0.04), MLNK: 3.68 (+0.03), RXN: 27.24 (-0.31), KTWO: 19.33 (-0.68), PANW: 140.73 (-2.41), YHOO: 43.44 (-0.72), WHR: 203.42 (-7.40), UA: 74.80 (-0.99), GILD: 101.81 (-1.61), R: 91.48 (-2.38), SIX: 45.97 (-0.79), DATA: 92.34 (-3.16), TW: 129.11 (-2.40), MA: 90.79 (-2.02), NVET: 10.17 (-0.13), IPGP: 95.80 (-2.02)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (-0.06), ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66), BIOC: 3.10 (-0.26), KKR: 23.71 (+0.04), NBG: 1.43 (-0.08), ARO: 4.04 (-0.01), ANFI: 10.28 (-0.92), HOT: 80.69 (-0.06), COUP: 9.77 (+0.10), URBN: 38.89 (+0.15), VSTM: 8.33 (+0.34), SYN: 2.45 (+0.10), ANTH: 6.12 (+0.59), SALE: 18.26 (+0.06), CGEN: 8.13 (-0.14), DF: 15.88 (-0.13), CJJD: 2.81 (-0.08), MERU: 2.36 (-0.27)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 3.11 (-0.10), BLUE: 113.14 (+0.91), ZIOP: 13.38 (-0.43), MYGN: 35.13 (+0.34), PSTI: 3.10 (-0.11), PFE: 33.97 (-0.50), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), ASPX: 69.14 (-0.32), MNKD: 5.47 (-0.26), HSP: 87.90 (+0.05), ZTS: 45.78 (-0.68), ANTM: 145.16 (-1.69), WMGI: 26.21 (-0.11), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), THOR: 39.50 (-0.83), TEVA: 56.40 (-0.11), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), ARNA: 4.32 (+0.09)
